

SERRÉTIA CLINICAL DATA

ENZYME	PUBLICATION	SUBJECTS	INTERVENTION	DURATION	ENDPOINTS	RESULTS
Serrapeptase	Al-Khateeb et al 2008	24	10,000 SPU 3x daily	7 days	Swelling and pain intensity due to surgery	After 7 days, the patients given serrapeptase showed improvement versus their placebo counterparts. Study concluded that serrapeptase reduced swelling and pain after surgery vs placebo.
Serrapeptase	Esch et al 1989	66	not specified	3 days	Swelling and pain intensity due to injury	After 3 days, serrapeptase had demonstrable effects on the levels of swelling vs those in the placebo control group.
Serrapeptase	Mazzone et al 1990	193	20,000 SPU 3x daily	7-8 days	Ear, nose and throat conditions	After 8 days, serrapeptase had demonstrable effects on the levels of pain and mucus secretion vs those in the placebo control group.
Serrapeptase	Tachibana et al 1984	174	20,000 SPU 3x daily	5 days	Swelling due to surgery	After 5 days, the patients given serrapeptase showed improvement versus their placebo counterparts. Study concluded that serrapeptase reduced swelling after surgery vs placebo.
Serrapeptase	Moriya et al 1994	n/a	n/a	n/a	Absorption	In vitro testing demonstrated that the enzyme can be absorbed into the bloodstream after oral administration.
Serrapeptase	Swamy et al 2008	n/a	n/a	n/a	Inflammation	Testing demonstrated the enzyme's ability to reduce inflammation in the paws of rats.
Serrapeptase	n/a	in vitro	n/a	n/a	Fibrinolytic Activity	In vitro testing has demonstrated strong fibrinolytic activity of serrapeptase. Further research into the benefits of the enzyme is recommended based on the outcome of this study.